Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. 1993

M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
Laboratoire d'Hématologie et INSERM U 331, Hôpital Cardio-vasculaire et Pneumologique Louis Pradel, B.P. Lyon Montchat, France.

Brief case histories of three patients aged 58, 38, and 44 years are reported. All underwent cardiovascular operations. Subsequently hemostasis test abnormalities developed between the seventh and eighth postoperative days after exposure to bovine thrombin used with fibrin glue. These were characterized by an increased activated partial thromboplastin time (64 to 147 seconds), prothrombin time (19 to 24 seconds), bovine thrombin time (> 120 seconds) and a markedly reduced factor V level (< 10% in two patients and 16% in the third patient). A patient plasma dilution of 1 in 200 with a normal plasma pool was necessary to correct bovine thrombin time. No fast-acting or progressive inhibitor against factor V could be detected by coagulation tests, and fresh frozen plasma perfusion had no effect. Plasmapheresis was performed preventatively to avoid bleeding, and factor V levels stabilized at around 50% after two to four exchanges. Immunologic studies showed that the inhibitors were directed not only against bovine factors but also against human ones. Therefore factor V decrease could have been the result of rapid clearance from the circulation of complexes formed with a nonneutralizing inhibitor that is not detected by clotting tests. These antibodies were purified by standard methods and immunoaffinity. Fast immunization could be explained by a prior sensitization to bovine thrombin exposure during previous operations. It is suggested that bovine thrombin used with fibrin glue contains small amounts of factor V and may be responsible for these abnormalities. This is in agreement with previous literature reports. However, these described neutralizing factor V inhibitors, which were easily detected.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005165 Factor V Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease. Coagulation Factor V,Proaccelerin,AC Globulin,Blood Coagulation Factor V,Factor 5,Factor Five,Factor Pi,Factor V, Coagulation
D005260 Female Females
D006348 Cardiac Surgical Procedures Surgery performed on the heart. Cardiac Surgical Procedure,Heart Surgical Procedure,Heart Surgical Procedures,Procedure, Cardiac Surgical,Procedure, Heart Surgical,Procedures, Cardiac Surgical,Procedures, Heart Surgical,Surgical Procedure, Cardiac,Surgical Procedure, Heart,Surgical Procedures, Cardiac,Surgical Procedures, Heart

Related Publications

M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
November 1993, British journal of haematology,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
June 1997, Thrombosis and haemostasis,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
January 2010, Congenital heart disease,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
October 1975, European journal of biochemistry,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
December 1989, Journal of cardiothoracic anesthesia,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
November 1990, Akusherstvo i ginekologiia,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
May 1987, The Annals of thoracic surgery,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
November 1990, Blood,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
November 1987, The Annals of thoracic surgery,
M Berruyer, and J Amiral, and P Ffrench, and J Belleville, and O Bastien, and J Clerc, and A Kassir, and S Estanove, and M Dechavanne
December 2010, Pediatric blood & cancer,
Copied contents to your clipboard!